HLYK HealthLynked Corp
Services-Offices & Clinics of Doctors of Medicine · OTC · SEC CIK 1680139 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-52.0%
TTM net income YoY-4.5%
TTM EPS YoY1.5%
Revenue 3-yr CAGR-43.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-202.3%
Net margin-351.6%
FCF margin—
EBITDA margin-196.7%
Returns
ROE—
ROA-234.0%
ROIC (approx.)—
Asset turnover0.67x
Leverage & solvency
Liabilities / assets641.2%
Debt / equity—
Current ratio0.52x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.35x
Accruals ratio-153.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $155,934 | $249,830 | $423,465 | $310,179 | $388,545 | $592,360 | $774,208 | $618,927 |
| SG&A expense | $435,920 | $517,489 | $847,281 | $453,610 | $500,736 | $451,755 | $629,415 | $546,196 |
| Operating income | -$535,016 | -$538,776 | -$700,813 | -$530,894 | -$529,586 | -$435,385 | -$617,389 | -$748,774 |
| Interest expense | $755 | $756 | — | — | $42,453 | $42,153 | — | — |
| Pretax income | — | — | — | — | — | — | — | -$1.23M |
| Net income | -$888,892 | -$819,705 | -$1.62M | -$676,477 | -$851,800 | -$701,038 | -$1.05M | -$1.23M |
| EBITDA | -$533,245 | -$528,547 | -$674,773 | -$504,440 | -$509,431 | -$408,147 | -$589,365 | -$720,338 |
| EPS (basic) | -0.29 | -0.28 | -0.56 | — | -0.30 | -0.25 | -0.37 | — |
| EPS (diluted) | -0.29 | -0.28 | -0.56 | — | -0.30 | -0.25 | -0.37 | — |
| Weighted avg. shares (diluted) | 3.10M | 2.94M | 2.90M | — | 2.83M | 2.82M | 2.82M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $16,594 | $12,844 | $23,973 | $37,136 | $10,911 | $20,201 | $22,270 | $76,241 |
| Inventory | $14,157 | $18,300 | $18,471 | $17,962 | $31,977 | $27,589 | $32,259 | $44,686 |
| Current assets | $1.54M | $1.54M | $1.54M | $1.55M | $1.54M | $1.56M | $1.57M | $1.64M |
| PP&E, net | $36,665 | $38,437 | $48,665 | $74,705 | $101,159 | $121,314 | $148,552 | $176,576 |
| Total assets | $1.58M | $1.59M | $1.63M | $1.70M | $1.85M | $1.85M | $2.06M | $2.22M |
| Current liabilities | $2.95M | $8.90M | $8.20M | $7.01M | $6.74M | $6.13M | $5.60M | $4.69M |
| Total liabilities | $10.10M | $9.35M | $8.65M | $7.46M | $7.20M | $6.60M | $6.19M | $5.35M |
| Shareholders' equity | -$8.53M | -$7.75M | -$7.02M | -$5.76M | -$5.43M | -$4.75M | -$4.14M | -$3.13M |
| Shares outstanding | 2.97M | 2.95M | 2.94M | 2.88M | 2.85M | 281.95M | 281.95M | 2.82M |
| Cash flow statement | ||||||||
| Operating cash flow | -$392,401 | -$350,133 | -$221,976 | -$419,430 | -$444,291 | -$417,536 | -$432,553 | -$743,602 |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | -$743,602 |
| Investing cash flow | — | — | — | — | — | — | — | $425,000 |
| Financing cash flow | $396,151 | $339,004 | $208,813 | $320,655 | $435,001 | $415,467 | $378,582 | $379,885 |
| Depreciation & amortization | $1,771 | $10,229 | $26,040 | $26,454 | $20,155 | $27,238 | $28,024 | $28,436 |
| Stock-based compensation | $75,599 | $88,237 | $297,522 | $93,216 | $4,694 | $5,267 | $7,126 | $18,294 |
Free plan shows the latest 8 periods; Pro shows all 43 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.